The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world outcomes of durvalumab or pembrolizumab plus gemcitabine and cisplatin (GemCis) in advanced biliary tract cancer (BTC).
 
Soyeon Kim
No Relationships to Disclose
 
Hyehyun Jeong
No Relationships to Disclose
 
Jaekyung Cheon
Research Funding - Bayer
 
Inkeun Park
Consulting or Advisory Role - Amgen; Astellas Pharma Korea; BMS pharmaceutical Korea; Boryung Pharmaceuticals; Chong Kun Dang Pharmaceutical Co; daiichi sankyo korea; Janssen; Merck; Ono Pharmaceutical; Samsung Bioepis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Boryung Pharmaceutical Co (Inst); Chong Kun Dang Pharmaceutical Co. (Inst)
 
Kyu-pyo Kim
No Relationships to Disclose
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Changhoon Yoo
Stock and Other Ownership Interests - OncoCross
Honoraria - AstraZeneca; Boehringer Ingelheim; Boryung Pharmaceuticals; Bristol-Myers Squibb; Eisai; Elevar therapeutics; Ipsen; MSD Oncology; Novartis; SERVIER
Consulting or Advisory Role - Abbisko Therapeutics; Qurient
Research Funding - AstraZeneca; Boehringer Ingelheim; Boryung Pharmaceuticals; Eisai; Lunit